Overview

Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin

Status:
Completed
Trial end date:
2021-10-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN).
Phase:
Phase 3
Details
Lead Sponsor:
Aurinia Pharmaceuticals Inc.
Treatments:
Calcineurin Inhibitors
Cyclosporine